Stemline Therapeutics (STML) Files $50M IPO
Get Alerts STML Hot Sheet
Join SI Premium – FREE
In a Form S-1 late Monday, Stemline Therapeutics (Nasdaq: STML) registered a $50 million initial public offering. The company plans to list on the NASDAQ under the symbol "STML."
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
The offering is being made through Oppenheimer and JMP Securities.
Stemline is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rectitude Holdings (RECT) Announces 2M Share IPO at $4-$6/sh
- BeiGene (BGNE) Receives EU Approval for Tislelizumab
- Travel firm Viking aims for up to $10.8 billion valuation in US IPO
Create E-mail Alert Related Categories
IPOsRelated Entities
JMP Securities, S1Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!